Earlier this week, Sprout Pharmaceuticals announced that the U.S. Food and Drug Administration had granted approval of Addyi (pronounced “ADD-ee,” as though the “i” weren’t there), a once-daily, non-hormonal pill for the treatment of low sexual desire in premenopausal women. The prescription drug, whose generic name is flibanserin (fly-BAN-ser-in), will go on sale October 17, 2015.
Other reporters have commented on the medical and business aspects of the announcement. Even The Onion, America’s finest news source, has weighed in. I’m here to talk about the Addyi name—its spelling, its pronunciation, and its brand qualities.